Modified-release dipyridamole combined with aspirin for secondary stroke prevention

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

BACKGROUND Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice da...

Dipyridamole + ASA for secondary prevention after a stroke or TIA

Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.

OBJECTIVES To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D. DATA SOURCES The previously published meta-analysis of indi...

Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke.

BACKGROUND AND PURPOSE The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent transient ischemic attack or minor stroke. It is unknown whether this also applies to patients with a disabling stroke. METHODS We reanalyzed the data of 5700 patients from ESPR...

Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.

study [8–10] proves otherwise. Therefore, based on a combination of currently available direct and indirect evidence, dipyridamole plus aspirin is the proper recommendation: it is not statistically in the best interests of the patient to prescribe monotherapy with either aspirin or clopidogrel. The only issue we see here is: which formulation of dipyridamole should be employed? We shall present...